RBC Capital Sees Merck (MRK) Returning to Growth Sooner Than Market Expects

Core Viewpoint - Merck & Co., Inc. is recognized as one of the best affordable dividend stocks, with positive analyst sentiment regarding its future growth potential and product pipeline [1]. Group 1: Analyst Coverage and Ratings - RBC Capital initiated coverage of Merck with an Outperform rating and a price target of $142, citing strong investor interest driven by upcoming product launches and Phase 3 trial results that may enhance earnings estimates [2]. - The firm believes that Merck's management has a solid track record, which supports the view that the company can return to growth in the early 2030s, contrasting with broader market expectations of a prolonged decline [2]. Group 2: Business Reorganization - Merck announced a reorganization into two divisions: one focusing on oncology, led by Keytruda, and the other on non-oncology treatments, aiming to reduce reliance on Keytruda and older drugs as patents near expiration [3]. - The company has significantly expanded its pipeline, tripling the number of programs in development since 2021, and has made strategic acquisitions worth approximately $10 billion to strengthen its portfolio [3]. Group 3: Historical Context - Merck previously spun off its women's health and biosimilars business into a separate entity, Organon, in 2021, indicating a history of strategic restructuring to enhance focus on core areas [4]. - The current restructuring does not include the animal health division, highlighting a targeted approach to business realignment [4].